ReviewFrontiers in pharmacology2026

Selegiline, a monoamine oxidase-B inhibitor as a modulator of metabolic reprogramming for cancer therapy: a review.

Jayanth Jayachandran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.